Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Teva
AstraZeneca
Healthtrust
Accenture
Julphar
Farmers Insurance
Deloitte
Argus Health

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,575,137

« Back to Dashboard

Which drugs does patent 8,575,137 protect, and when does it expire?

Patent 8,575,137 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-seven countries.
Summary for Patent: 8,575,137
Title:Composition for inhalation
Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
Inventor(s): Govind; Nayna (Loughborough, GB), Marlow; Maria (Loughborough, GB)
Assignee: AstraZeneca AB (Macclesfield, GB)
Application Number:13/411,939
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Delivery;

Drugs Protected by US Patent 8,575,137

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,575,137

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0200312Feb 1, 2002

Non-Orange Book US Patents Family Members for Patent 8,575,137

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,759,328 Composition for inhalation ➤ Subscribe
8,143,239 Composition for inhalation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,575,137

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 79445 ➤ Subscribe
Slovenia 2036549 ➤ Subscribe
Slovenia 1474117 ➤ Subscribe
Sweden 0200312 ➤ Subscribe
Russian Federation 2301673 ➤ Subscribe
Russian Federation 2004122921 ➤ Subscribe
Portugal 2036549 ➤ Subscribe
Portugal 1474117 ➤ Subscribe
Poland 211836 ➤ Subscribe
Poland 372118 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Mallinckrodt
Fish and Richardson
Argus Health
UBS
Medtronic
Accenture
Merck
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot